• <xmp id="sqoyg">
  • <xmp id="sqoyg"><nav id="sqoyg"></nav>
    • 24小時急診熱線 : +86 10 59850333
    • 預約服務熱線 : 400-8762-747
    當前位置 : 首頁 > 媒體報道
    【PCV23】Pneumococcal Vaccine "PNEUMOVAX" Available Now


    Invasive pneumococcal disease (IPD) is a group of illnesses caused by bacteria called pneumococcus bacteria. It can spread through the air from an infected person by droplets from a cough or sneeze. The bacteria can enter your body through the mouth, throat, or eyes, and may invade parts of the body that are normally free from infection.


    Pneumococcal disease is common in young children.  But, believe it or not, older adults are at greater risk of serious illness or death and need protection too. Depending on what organ or part of the body is infected, pneumococcal disease will cause any of several serious illnesses, including:

    • Meningitis, an infection of the covering of the brain and spinal cord that can lead to confusion, coma, and death as well as other physical effects, such as blindness or paralysis

    • Pneumonia, an infection of the lungs that creates cough, fever, and difficulty breathing

    • Otitis Media, a middle ear infection that can cause pain, swelling, sleeplessness, fever, and irritability

    • Bacteremia, a blood infection that can rapidly progress to Sepsis.

     

    INTRODUCING

    Pneumococcal Vaccine 
    Polyvalent 23

    PNEUMOVAX





    Brief History of Vaccine


    PCV7 was first licensed for use by the FDA in 2000. Studies found it to be highly effective in the prevention of invasive pneumococcal disease in young children affording almost complete protection (96%) to healthy children, and 81% protection in children with sickle cell disease, an at-risk group for pneumococcal disease. It was also shown to be effective against antibiotic-resistant pneumococcal infections too.

     

    Between 2000 and 2010, an increase was seen by serotypes not covered by PCV7, which brought about PCV13. PCV13 replaced PCV7 in 2010. Experts estimate PCV13 prevented more than 30,000 cases of invasive infection and 3,000 deaths in the first 3 years of use.

     

    In 2011, the FDA approved PCV13 for use in adults 50rys or older. Studies showed the vaccine to be effective in 9 in 20 vaccinated against pneumococcal pneumonia.

     

    PCV23 covers 23 serotypes of pneumococcal infection and has been shown to protect between 10 to 17 in 20 adults with healthy immune systems against invasive disease caused by the vaccine serotypes.



    PCV23 AVAILABLE NOW

    By Appointment @OASIS

    400 8762 747



    PNEUMOVAX


    ADULTS 14YRS & UP

    INTERNAL MEDICINE

    720 RMB





    CHILDREN 2YRS & UP
    PEDIATRICS

    Prices may vary

    Inoculation dependent on Pediatrician Consult



    久久一本人碰碰人碰_久久一本人碰碰人_久久一本通凹凸一道久视